Multiple Sclerosis Clinical Trial

Multi-center Database Registry to Study Thalamus Changes Using AI in MS

Summary

In this study the Investigator's propose to validate a newly developed approach, DeepGRAI (Deep Gray Rating via Artificial Intelligence), to simplify the calculation of thalamic atrophy in a clinical routine and allow academic and community neurologists to plan, perform, and publish novel and influential clinical research using data from clinical routine, by employing deep machine learning (DML) pattern recognition (PR) information through use of artificial intelligence (AI).

View Full Description

Full Description

This is a multicenter, observational, retrospective, cross-sectional and longitudinal population study of brain volume changes in MS patients. The retrospective electronic medical record (EMR) and brain MRI image data will be collected at participating MS centers and de-identified data will be integrated into a central research database. All the data to be integrated into the database has already been collected by physicians at the centers as part of their routine clinical practice and is thus non-interventional and retrospective in nature. This new approach will be compared to existing approaches of brain volume measurement that are currently widely available. This breakthrough approach would lead to potentially abandoning classis measurement of the specific brain volume structures and would be applicable in real-time in clinical routine.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient diagnosed with relapsing-remitting (RR) MS

Access to raw MRI index scan images that meet all of the below criteria

MRI scan image acquired at index
The scan was performed on 1.5T or 3T scanners
The scan must have a T2-FLAIR sequence

Access to raw MRI post-index scan images that meet all of the below listed criteria

MRI scan image acquired at post-index
The scan was performed on 1.5T or 3T scanners
The scan must have a T2-FLAIR sequence
Age 18-85 at index
Fulfilling the MRI scan and clinical data requirements outlined in Table 2
None of the exclusion criteria

Exclusion Criteria:

Have received an investigational drug or experimental procedure during the study period
Women who were pregnant, or lactating at index or during the post-index period
Patients who had a relapse 30 days prior to the selected MRI scan date
Patients who received steroid treatment 30 days prior to the selected MRI scan date
Presence of other neurologic diseases affecting CNS

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

1000

Study ID:

NCT03920995

Recruitment Status:

Completed

Sponsor:

University at Buffalo

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University at Buffalo
Buffalo New York, 14203, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

1000

Study ID:

NCT03920995

Recruitment Status:

Completed

Sponsor:


University at Buffalo

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.